aBLA Filing Intelligence & Biosimilar Opportunity

Tecvayli

Teclistamab-Cqyv

Anticancer

Injection Injectable

Approval Date

25-Oct-22

Data Exclusivity Expiry

25-Oct-26

Market Exclusivity Expiry

25-Oct-34

Commercial snapshot

Market performance & projections

Revenue ($M)

670

CAGR (%)

0.4891

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

1078

2027

1886

2028

2553

2029

3294

2030

4252

2031

4796

2032

5289

Molecule profile

Details & specifications

Molecule

Teclistamab-Cqyv

Innovator

JANSSEN BIOTECH, INC.

Dosage Form

Injection Injectable

Strength

30 mg/3 mL (10 mg/mL), 153 mg/1.7 mL (90 mg/mL)

Therapeutic Category

Anticancer

Usage

To treat relapsed or refractory multiple myeloma among adults who have received at least four specific lines of therapy

Good to know

Frequently asked questions

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.

Why Spring Bio Solution

Intelligence you can file on

Verified regulatory data

Milestones tracked against primary FDA sources and refreshed continuously.

Analyst-built projections

Seven-year sales outlooks modeled by our pharma intelligence team.

First-to-file focus

Exclusivity windows framed around the decisions generics teams actually make.

Partnership on demand

From API sourcing to dossier support — one request starts the conversation.